Small Molecule Inhibition of GSK-3 Specifically Inhibits the Transcription of Inhibitory Co-receptor LAG-3 for Enhanced Anti-tumor Immunity
Open Access
- 1 February 2020
- journal article
- research article
- Published by Elsevier in Cell Reports
- Vol. 30 (7) , 2075-2082.e4
Abstract
No abstract availableKeywords
Funding Information
- Cancer Research UK (C11071/A20105)
This publication has 36 references indexed in Scilit:
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune EscapeCancer Research, 2012
- Novel cancer immunotherapy agents with survival benefit: recent successes and next stepsNature Reviews Cancer, 2011
- T-bet in diseaseNature Immunology, 2011
- Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infectionNature Immunology, 2011
- PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in miceJournal of Experimental Medicine, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impairedBlood, 2009
- LAG-3 Regulates Plasmacytoid Dendritic Cell HomeostasisThe Journal of Immunology, 2009
- Reinvigorating exhausted HIV-specific T cells via PD-1–PD-1 ligand blockadeJournal of Experimental Medicine, 2006
- The CD4‐related molecule, LAG‐3 (CD223), regulates the expansion of activated T cellsEuropean Journal of Immunology, 2003